RecruitingNot Applicable

RAB Versus Ultrathin Bronchoscopy With VBN in the Diagnosis of PPNs

China186 participantsStarted 2025-07-02

Plain-language summary

The purpose of this study is to evaluate whether the diagnostic yield of robotic-assisted bronchoscopy is not inferior to that of the virtual bronchoscopic navigation combined with ultrathin bronchoscopy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years, regardless of gender;
✓. Patients with peripheral lung nodules of suspected malignancy on chest CT who require non-surgical biopsy;
✓. Patients who voluntarily consent to undergo bronchoscopy and meet the requirements for the bronchoscopy;
✓. Patients should understand the purpose of the trial, demonstrate good compliance with the examinations and follow-ups, and voluntarily participate in the clinical trial and sign the informed consent form.

Exclusion criteria

✕. Presence of contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina; severe cardiac or pulmonary dysfunction; severe hypertension and arrhythmias; uncorrectable bleeding tendencies or severe coagulation disorders (such as platelet count \<60×10\^9/L), uremia; severe pulmonary artery hypertension; severe superior vena cava syndrome; intracranial hypertension; acute cerebrovascular events; aortic dissection or aneurysm; multiple bullae; extreme systemic exhaustion;
✕. Patients with pure ground-glass nodules suspected of malignancy on chest CT;
✕. Female patients who are breastfeeding, pregnant, or planning pregnancy;
✕. Patients with electromagnetic active implantable medical devices;
✕. Subjects allergic to anesthetics; or with a history of multiple severe allergies, hereditary allergy history;
✕. Those who have participated in or are currently participating in drug clinical trials within 3 months before screening, or have participated in other medical device clinical trials within 30 days;
✕. Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.

What they're measuring

Diagnostic yield

Timeframe: 14 days post-procedure

Trial details

NCT IDNCT06962436

SponsorShanghai Chest Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11

Contact for this trial

Xiaoxuan Zheng

18930859598 milozheng9140@163.com

View on ClinicalTrials.gov More Peripheral Pulmonary Nodules trials